Tesamorelin

Tesamorelin is a synthetic analog of the full-length, 44-amino-acid human growth-hormone-releasing hormone, GHRH(1-44), modified with a trans-3-hexenoyl group at its amino terminus to resist degradation by dipeptidyl peptidase-4, the enzyme responsible for the minutes-long half-life of the native hormone. It was developed by the Canadian biopharmaceutical company Theratechnologies under the development code TH9507 and, unlike every other peptide in this queue, completed a full clinical development program and received FDA approval in 2010 under the brand name Egrifta, specifically for reducing excess abdominal visceral fat in HIV-infected patients with lipodystrophy, a common and disfiguring complication of long-term antiretroviral therapy and HIV infection itself. A reformulated version, Egrifta SV, using a simplified needle-free reconstitution device, was approved later to reduce administration burden and injection-site complications associated with the original formulation. Tesamorelin remains, as of the most recent public information, the only growth-hormone-releasing-hormone analog approved anywhere for a body-composition-related indication, giving it a fundamentally different regulatory and evidence status than the compounded and research-market GHRH analogs, such as CJC-1295 and sermorelin, that it is sometimes grouped with in general discussion of growth hormone peptides.

The core mechanism of tesamorelin is activation of the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, triggering the same pulsatile growth hormone release pathway engaged by endogenous GHRH and by other GHRH-based analogs. Downstream, the growth hormone pulse stimulates hepatic and peripheral production of insulin-like growth factor 1 (IGF-1), the hormone most directly implicated in growth hormone's metabolic and anabolic effects; the GH1, GHR, and IGF1 genes together form the signaling axis tesamorelin engages indirectly through pituitary receptor activation. What distinguishes tesamorelin's clinical profile mechanistically is that growth hormone and IGF-1 elevation appears to promote lipolysis preferentially in visceral adipose tissue relative to subcutaneous fat, a depot-selective effect that underlies the specific visceral-fat-reduction outcome measured across its trial program, rather than a generalized whole-body fat-loss effect. A more recently characterized extension of this mechanism links growth hormone axis stimulation to reduced hepatic fat content and, in one trial, reduced liver fibrosis progression, broadening tesamorelin's relevant physiology from visceral fat specifically to hepatic lipid metabolism more generally.

The tesamorelin human evidence base is unusually strong and specific among the peptides in this queue. A pair of identical, multicenter, randomized, double-blind, placebo-controlled phase 3 trials was conducted; the first, published in the New England Journal of Medicine in 2007, enrolled 412 HIV-infected adults with excess abdominal fat and found that once-daily 2-milligram subcutaneous tesamorelin reduced visceral adipose tissue, measured by computed tomography, by approximately 15 to 18 percent relative to placebo over 26 weeks, alongside modest lipid improvements and improved patient-reported appearance-related distress. A pooled analysis of both trials with extension data, published in 2010, confirmed the durability of this effect through 52 weeks of continued treatment and, importantly, documented that visceral fat re-accumulated toward baseline within months after treatment was stopped, establishing that tesamorelin sustains an ongoing physiological effect rather than producing a one-time structural change. Building on this foundation, a 2014 randomized trial published in JAMA found that 12 months of tesamorelin reduced liver fat content measured by magnetic resonance spectroscopy, and a 2021 randomized trial published in Annals of Internal Medicine, enrolling HIV-infected patients with biopsy-confirmed nonalcoholic fatty liver disease, found that tesamorelin improved liver histology and slowed fibrosis progression relative to placebo, a biopsy-confirmed, disease-modifying endpoint that few peptides in this queue can claim.

From a pharmacokinetic and regulatory standpoint, tesamorelin is given by subcutaneous injection into the abdomen once daily at bedtime, has a short terminal half-life on the order of tens of minutes despite its stabilizing modification, and is not orally bioavailable. It is approved by the FDA specifically for HIV-associated lipodystrophy and, unlike compounded or research-market GHRH analogs, is manufactured under standard pharmaceutical quality control as a prescription medication with an approved labeling document specifying its contraindications, warnings, and monitoring requirements. It is not approved, and has not been demonstrated effective in a completed trial, for fat loss, muscle gain, athletic performance, sleep, skin quality, or general anti-aging benefit in HIV-negative populations; any such off-label use represents a repurposing of an HIV-specific drug outside its studied population and indication, carrying the same class-level growth-hormone-axis risks (glucose intolerance, arthralgia, edema, and the theoretical malignancy-related caution) without the corresponding trial-confirmed benefit documented for the approved indication. As an FDA-approved growth hormone secretagogue, tesamorelin is also included within the World Anti-Doping Agency prohibited list applicable to the growth hormone secretagogue class, relevant to any athlete considering its use outside a legitimate HIV-related prescription.

Mechanism of Action

GHRH(1-44) Backbone and the Trans-3-Hexenoyl Stabilizing Modification

Tesamorelin is built on the full-length, biologically active 44-amino-acid sequence of human growth-hormone-releasing hormone, GHRH(1-44), in contrast to GHRH(1-29)-based analogs such as sermorelin and CJC-1295, which use only the shorter 29-amino-acid fragment. To address the same enzymatic instability that limits native GHRH to a half-life of only a few minutes, tesamorelin carries a trans-3-hexenoyl group attached to its amino terminus, a modification that confers resistance to cleavage by dipeptidyl peptidase-4, the protease primarily responsible for GHRH inactivation in plasma. This modification stabilizes the peptide against enzymatic degradation without introducing an albumin-binding mechanism, so tesamorelin retains a relatively short terminal half-life, on the order of tens of minutes, distinguishing its pharmacokinetic strategy from the multi-day albumin-bound half-life achieved by CJC-1295 with DAC.

GHRHR Activation and the Growth Hormone / IGF-1 Axis

Like other GHRH-based analogs, tesamorelin binds and activates the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, triggering synthesis and pulsatile release of growth hormone. Downstream, this growth hormone acts on growth hormone receptors (GHR) in the liver and peripheral tissues, activating JAK2/STAT5 and phosphoinositide 3-kinase/AKT signaling that stimulates hepatic and local production of insulin-like growth factor 1 (IGF-1). Across the tesamorelin phase 3 trial program, sustained IGF-1 elevation served as the primary pharmacodynamic marker confirming ongoing biological activity, and IGF-1 monitoring remains part of standard clinical management under the approved labeling.

Depot-Selective Lipolysis in Visceral Adipose Tissue

A defining feature of tesamorelin’s clinical effect is that growth hormone and IGF-1 elevation appears to promote lipolysis preferentially in visceral adipose tissue relative to subcutaneous fat depots. Visceral fat is more metabolically active and more responsive to growth-hormone-driven lipolytic signaling than subcutaneous fat, a depot-selective sensitivity that is thought to explain why tesamorelin phase 3 trials measured a specific, substantial reduction in visceral adipose tissue by computed tomography rather than a generalized, uniform reduction in total body fat.

Hepatic Lipid Metabolism and Fibrosis

A more recently characterized extension of tesamorelin mechanism links growth hormone axis stimulation to reduced hepatic fat content and, in a biopsy-confirmed trial, slowed liver fibrosis progression in HIV-associated nonalcoholic fatty liver disease. The proposed mechanism involves growth hormone and IGF-1 broader roles in hepatic lipid handling and insulin sensitivity, though the precise molecular pathway connecting pituitary GHRHR activation to reduced hepatic fibrosis has not been as fully characterized as the visceral-fat mechanism, and this hepatic benefit has been demonstrated specifically in HIV-infected patients with concurrent liver disease rather than in a general nonalcoholic fatty liver disease population.

Clinical Evidence

Pivotal Phase 3 Trial Program

The primary evidence supporting tesamorelin approval comes from a pair of identical, multicenter, randomized, double-blind, placebo-controlled phase 3 trials; the first, published in the New England Journal of Medicine in 2007, enrolled 412 HIV-infected adults with excess abdominal fat. Once-daily subcutaneous tesamorelin at 2 milligrams reduced visceral adipose tissue, measured by computed tomography, by approximately 15 to 18 percent relative to placebo over 26 weeks, alongside modest reductions in triglycerides and improvement in a validated patient-reported measure of appearance-related distress. This trial program represents one of the most rigorous human efficacy datasets available for any peptide in this queue.

Long-Term Extension and the Treatment-Dependent Effect

A pooled analysis of both pivotal trials, published in 2010 with 52-week extension data, confirmed that continued tesamorelin treatment sustained the visceral-fat-reduction effect through a full year of therapy. Critically, this analysis and a separate long-term safety extension study also documented that stopping tesamorelin led to visceral fat re-accumulating toward pretreatment levels within a matter of months, establishing that the clinical benefit of tesamorelin depends on ongoing administration and does not represent a durable, one-time structural change to body composition.

Extension to Liver Fat and Histology

A 2014 randomized, placebo-controlled trial published in JAMA found that 12 months of tesamorelin treatment reduced liver fat content, measured by proton magnetic resonance spectroscopy, in HIV-infected patients with abdominal fat accumulation, a population with a high prevalence of concurrent nonalcoholic fatty liver disease. Building on this finding, a 2021 randomized trial published in Annals of Internal Medicine, enrolling HIV-infected patients with biopsy-confirmed nonalcoholic fatty liver disease, found that tesamorelin improved liver histology and reduced the rate of fibrosis progression compared with placebo. This biopsy-confirmed, disease-modifying outcome is among the strongest categories of human evidence available for any peptide in this entire queue, though it applies specifically to HIV-infected patients with concurrent liver disease rather than to a general population.

Safety and Tolerability

Across the pivotal trials, the most common adverse effects reported more frequently with tesamorelin than placebo included injection-site reactions (erythema, pruritus, and pain), arthralgia, myalgia, and peripheral edema. Increases in blood glucose have been observed, consistent with the known insulin-antagonizing effect of growth hormone, warranting glucose monitoring during treatment. Hypersensitivity reactions, including anaphylaxis, have been reported in postmarketing experience. The overall safety profile across more than a decade of clinical use and multiple trials is better characterized than that of any other peptide in this queue, reflecting its status as an approved pharmaceutical subject to ongoing pharmacovigilance.

Regulatory Status

Tesamorelin, marketed as Egrifta and, in a reformulated needle-free-reconstitution presentation, as Egrifta SV, is approved by the United States Food and Drug Administration specifically for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy. This approval, granted in 2010 and based on the phase 3 trial program described above, makes tesamorelin the only growth-hormone-releasing-hormone analog in this queue, and one of very few peptides overall, with a genuine FDA-approved indication supported by pivotal human trial data. It is manufactured under standard pharmaceutical quality control as a prescription medication, with an approved labeling document specifying dosing, contraindications, warnings, and monitoring requirements. Tesamorelin is not approved for use outside HIV-associated lipodystrophy, and any use for general fat loss, muscle gain, athletic performance, or anti-aging purposes in HIV-negative individuals is off-label and unsupported by the trial evidence, which was generated exclusively in HIV-infected populations. As an approved growth hormone secretagogue, tesamorelin is included within the World Anti-Doping Agency prohibited list applicable to the broader growth hormone secretagogue class, a status relevant to any athlete considering its use even under a legitimate medical prescription.

Tesamorelin versus CJC-1295 and Sermorelin

Tesamorelin, CJC-1295, and sermorelin all activate the same GHRHR target, but their regulatory and evidence status differ sharply. Tesamorelin is the only one of the three to complete a full phase 3 program and gain FDA approval, giving it substantially more human trial data, a longer track record of pharmacovigilance, and a formal safety and monitoring framework absent from the other two. Sermorelin was formerly FDA-approved for pediatric growth hormone deficiency evaluation before being withdrawn from the market for commercial reasons, retaining a smaller historical approval record than tesamorelin. CJC-1295 never advanced beyond a single small dose-escalation trial in healthy adults and is available only through compounding and research-chemical channels. Structurally, tesamorelin is also distinct in using the full-length GHRH(1-44) backbone with a dipeptidyl-peptidase-resistant modification, whereas CJC-1295 and sermorelin are both based on the shorter GHRH(1-29) fragment; CJC-1295 with DAC further diverges by using albumin binding to achieve a multi-day half-life that neither tesamorelin nor sermorelin shares.

Dosing Guidance

The FDA-approved dosing regimen, established across the pivotal phase 3 trial program, is 2 milligrams administered by subcutaneous injection into the abdomen once daily at bedtime, continued for as long as clinical benefit and tolerability are maintained. This is one of the few dosing regimens among the peptides in this queue with direct, repeated confirmation across multiple large randomized trials rather than reliance on compounding-market convention. Clinical benefit is contingent on continued administration; trial extension data documented that visceral fat re-accumulates toward pretreatment levels within months of discontinuation. No alternative dose, frequency, or cycled schedule has been established as safe or effective in a completed trial, and tesamorelin use outside its approved HIV-associated lipodystrophy indication has not been studied at this or any dose in the populations using it that way.